OTLC OTC
Oncotelic Therapeutics, Inc.
1W: -17.0%
1M: -40.7%
3M: -49.9%
YTD: -73.0%
1Y: -69.5%
3Y: -30.0%
5Y: -83.8%
$0.02
-0.00 (-1.41%)
Weekly Expected Move ±11.9%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
37 relationships37
As Filer
counterparties named
0
As Counterparty
mentioned by others
6
Rel. Types
2021-03-26
Earliest Filing
2026-04-02
Latest Filing
partner: 18
investor: 13
target: 2
licensee: 2
acquirer: 1
supplier: 1
Counterparties (Filed by OTLC)
37 relationshipsCompanies named in OTLC's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| TechForce Robotics, Inc. | — | partner | Robotics engineering company entering joint development agreement | 2026-04-02 | View |
| Oncotelic Therapeutics, Inc. | OTLC | partner | Biopharmaceutical and AI platform company entering joint development agreement | 2026-04-02 | View |
| ONCOTELIC THERAPEUTICS, INC. | OTLC | partner | Company issuing senior secured promissory note and warrants | 2026-01-29 | View |
| MAST HILL FUND, L.P. | — | investor | Buyer purchasing the note and warrants | 2026-01-29 | View |
| Oncotelic Therapeutics, Inc. | OTLC | partner | Party to the First Amendment to Independent Contractor Agreement | 2026-01-06 | View |
| Jefferson Capital Ventures, LLC | — | partner | Party to the First Amendment to Independent Contractor Agreement | 2026-01-06 | View |
| Oncotelic Therapeutics, Inc. | OTLC | target | Company conducting private placement offering of units, notes, and warrants. | 2025-12-09 | View |
| EdgePoint AI, Inc. | — | partner | Consolidated minority owned subsidiary of Oncotelic; units include convertible notes and warrants for EdgePoint common s | 2025-12-09 | View |
| Oncotelic Therapeutics, Inc. | OTLC | acquirer | Company entering into Independent Contractor Agreement to retain strategic management consulting services. | 2025-08-12 | View |
| Jefferson Capital ventures, LLC. | — | partner | Contractor providing strategic management consulting services in exchange for equity and cash compensation. | 2025-08-12 | View |
| Fourth Man, LLC | — | investor | Issued a convertible promissory note for $0.25 million | 2022-04-04 | View |
| JH Darbie & Co., Inc. | — | partner | Finder's fee agreement for the securities purchase | 2022-04-04 | View |
| Talos Victory Fund, LLC | — | investor | Prior issuer of convertible promissory notes | 2022-04-04 | View |
| Mast Hill Fund, LP | — | investor | Prior issuer of convertible promissory notes | 2022-04-04 | View |
| FirstFire Global Opportunities Fund, LLC | — | investor | Issued a convertible promissory note for $0.25 million | 2021-12-15 | View |
| Fourth Man, LLC | — | investor | Issued a convertible promissory note for $0.25 million | 2021-12-15 | View |
| JH Darbie & Co., Inc. | — | partner | Finder's fee agreement for the financing round | 2021-12-15 | View |
| Talos Victory Fund, LLC | — | investor | Prior issuer of a convertible promissory note | 2021-12-15 | View |
| Mast Hill Fund, LP | — | investor | Prior issuer of a convertible promissory note | 2021-12-15 | View |
| Blue Lake Partners, LLC | — | investor | Issued a convertible promissory note for $0.25 million | 2021-12-15 | View |
| Synergy Healthcare Innovations, LLC | — | partner | Notified as a copy recipient in the agreement | 2021-10-28 | View |
| Golden Mountain Partners, LLC | — | investor | Purchased an unsecured convertible note from Oncotelic Therapeutics, Inc. | 2021-09-27 | View |
| Covance Pharmaceutical Research and Development (Beijing) Co., Ltd | — | supplier | Contract Research Organization receiving loan proceeds for clinical trial services. | 2021-09-27 | View |
| Oncotelic Therapeutics, Inc. | OTLC | licensee | Oncotelic will in-license Autotelic's intra-nasal drug and delivery system for Parkinson's Disease, erectile dysfunction | 2021-09-03 | View |
| Autotelic Inc. | — | licensee | Autotelic will out-license its product comprising of the intra-nasal drug and delivery system related to nasal apomorphi | 2021-09-03 | View |
| Geneva Roth Remark Holdings, Inc. | — | investor | Issued a Convertible Promissory Note and entered into a Securities Purchase Agreement. | 2021-07-02 | View |
| EdgePoint AI, Inc. | — | partner | Received units consisting of common stock and warrants in a financing agreement. | 2021-07-02 | View |
| J.H. Darbie & Co., Inc. | — | partner | Received additional Oncotelic Warrants as placement agent. | 2021-07-02 | View |
| ONCOTELIC THERAPEUTICS, INC. | OTLC | partner | Company issuing convertible notes | 2021-06-01 | View |
| GENEVA ROTH REMARK HOLDINGS, INC. | — | investor | Buyer purchasing convertible notes | 2021-06-01 | View |
| Peak One Opportunity Fund, L.P. | — | investor | Investor purchasing up to $10,000,000 of the company's common stock | 2021-05-07 | View |
| Oncotelic Therapeutics, Inc. | OTLC | target | Company issuing and selling common stock to the investor | 2021-05-07 | View |
| Peak One Investments, LLC | — | partner | Entity receiving 125,000 commitment shares as part of the agreement | 2021-05-07 | View |
| J H Darbie & Co., Inc. | — | partner | Exclusive placement agent for the Company in placing the Offering. | 2021-03-26 | View |
| Texas Capital Bank, N.A. | — | partner | Bank acting as the Escrow Agent for the Offering funds. | 2021-03-26 | View |
| EdgePoint AI, Inc. | — | partner | Wholly owned subsidiary of Mateon Therapeutics, Inc. issuing Common Stock included in the Units. | 2021-03-26 | View |
| Mateon Therapeutics, Inc. | — | partner | Company conducting the private placement offering of Units. | 2021-03-26 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-04 | Material Agreement; Financial Obligation; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-07-14 | Other Events; Exhibits | View | |
| 2026-07-14 | Unregistered Equity Sales; Officer/Director Change; Exhibits | View | |
| 2026-06-29 | Material Agreement; Financial Obligation; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-05-05 | Material Agreement; Acquisition/Disposition; Unregistered Equity Sales; Exhibits | Agreement Acquisition | View |
| 2026-04-16 | Other Events; Exhibits | View | |
| 2026-04-02 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-03-30 | Other Events; Exhibits | View | |
| 2026-03-30 | Other Events; Exhibits | View | |
| 2026-01-29 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2026-01-26 | Entry into Material Definitive Agreement; Departure/Election of Directors; Appointment of Officers; | Agreement | View |
| 2026-01-07 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2026-01-06 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2026-01-06 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2025-12-30 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2025-12-23 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-09 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2025-10-22 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-12 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2025-08-06 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR